
The latest announcement is out from Allergy Therapeutics ( ($GB:AGY) ). Allergy Therapeutics reported a return to faster growth in the year to 30 June 2026, with revenues expected to
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AGYTF | Allergy Therapeutics | 0.15 | 0.03 | 27.27% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.15 | +27.27% |

The latest announcement is out from Allergy Therapeutics ( ($GB:AGY) ). Allergy Therapeutics reported a return to faster growth in the year to 30 June 2026, with revenues expected to

Allergy Therapeutics ( ($GB:AGY) ) has shared an announcement. Allergy Therapeutics has appointed Helge Weiner-Trapness as Executive Chairman, replacing long-serving Non-Executive Chairman Peter Jensen OBE, who will remain on the

An announcement from Allergy Therapeutics ( ($GB:AGY) ) is now available. Allergy Therapeutics has granted a new long-term incentive plan award to chief financial officer Shaun Furlong to recognise heightened

Allergy Therapeutics ( ($GB:AGY) ) just unveiled an announcement. Allergy Therapeutics will showcase data from its pollen and food allergy research portfolio at the EAACI Congress 2026 in Istanbul, underscoring

An update from Allergy Therapeutics ( ($GB:AGY) ) is now available. Allergy Therapeutics reported interim revenues of £36.3 million for the six months to 31 December 2025, up 7% despite

An announcement from Allergy Therapeutics ( ($GB:AGY) ) is now available. Allergy Therapeutics has reported an internal reorganisation within major shareholder ZQ Group, which transferred most of the company’s shares

An update from Allergy Therapeutics ( ($GB:AGY) ) is now available. Allergy Therapeutics reported positive biomarker data from its Phase I/IIa PROTECT trial of VLP Peanut, showing strong and consistent

Allergy Therapeutics ( ($GB:AGY) ) has issued an update. Allergy Therapeutics will present new clinical and biomarker data from its pollen and food-allergy research pipeline at the 2026 American Academy

The latest update is out from Allergy Therapeutics ( ($GB:AGY) ). Allergy Therapeutics has amended its existing loan agreement with Hayfin, replacing an uncommitted £20m line with a new committed

The latest announcement is out from Allergy Therapeutics ( ($GB:AGY) ). Allergy Therapeutics has strengthened its leadership and governance structure with the appointment of veteran investment banker Helge Weiner-Trapness as
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $116.48M | ― | ― | -1.10 | -1.59 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.